{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:50:54Z","timestamp":1761760254867,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Dutch Ministry of Health, Welfare, and Sport","doi-asserted-by":"publisher","award":["SP332770"],"award-info":[{"award-number":["SP332770"]}],"id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: The Dutch National Immunisation Programme (NIP) aims to protect children against severe infectious diseases. As with all vaccines, adverse events following immunisation (AEFIs) may occur with the use of vaccines in the NIP. Safety of the vaccines is monitored by The Netherlands Pharmacovigilance Centre Lareb. This study aimed to systematically document AEFIs following administration of the MMR and DT-IPV vaccines, which are given simultaneously at the age of 9 years. Methods: A cohort event monitoring (CEM) study was performed, employing a longitudinal cohort design. Parents or guardians of 9-year-olds receiving the MMR and DT-IPV vaccines completed questionnaires following vaccination to report the presence or absence of AEFI. Results: AEFIs were reported for more than 73% of children given an MMR and DT-IPV vaccination. The great majority of the reported reactions were non-serious and self-limiting and consistent with those listed in the official product information for the MMR and DT-IPV vaccines. Injection site reactions were significantly more frequent at the site of the DT-IPV vaccination than the MMR vaccination. AEFIs were mostly perceived as little or moderately burdensome. Conclusions: AEFIs very frequently occurred after MMR and DT-IPV vaccination. This study provides further insight into the timing and duration of AEFIs after MMR and DT-IPV vaccination. In addition, detailed insight into the adverse event profile of these vaccines is provided, which helps to set realistic expectations for children and their parents or caretakers who follow the NIP and helps health professionals in their communication regarding AEFIs.<\/jats:p>","DOI":"10.3390\/ph18111635","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:38:22Z","timestamp":1761759502000},"page":"1635","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Cohort Event Monitoring of MMR and DT-IPV Vaccination at 9 Years of Age in The Netherlands"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5334-1840","authenticated-orcid":false,"given":"Monika","family":"Raethke","sequence":"first","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Gorter","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9029-4713","authenticated-orcid":false,"given":"Rachel","family":"Kalf","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3815-9434","authenticated-orcid":false,"given":"Leontine van","family":"Balveren","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9912-3106","authenticated-orcid":false,"given":"Sanne","family":"Boetzkes","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-5261","authenticated-orcid":false,"given":"Rana","family":"Jajou","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-3224","authenticated-orcid":false,"given":"Florence","family":"van Hunsel","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH \u2019s-Hertogenbosch, The Netherlands"},{"name":"Department of PharmacoTherapy\u2014Epidemiology & Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Broerstraat 5, 9712 CP Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"ref_1","unstructured":"RIVM (2025, February 10). Rijksvaccinatieprogramma. Available online: https:\/\/rijksvaccinatieprogramma.nl\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1473-3099(16)00027-X","article-title":"Effect of vaccination programmes on mortality burden among children and young adults in The Netherlands during the 20th century: A historical analysis","volume":"16","author":"McDonald","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/EDE.0000000000000778","article-title":"Estimating the Population-Level Effectiveness of Vaccination Programs in The Netherlands","volume":"29","author":"McDonald","year":"2018","journal-title":"Epidemiology"},{"key":"ref_4","first-page":"1132","article-title":"The first effect of the national vaccination campaign against meningococcal-C disease: A rapid and sharp decrease in the number of patients","volume":"147","author":"Spanjaard","year":"2003","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100556","DOI":"10.1016\/j.jvacx.2024.100556","article-title":"A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements","volume":"20","author":"Pluijmaekers","year":"2024","journal-title":"Vaccine X"},{"key":"ref_7","unstructured":"RIVM (2025, March 31). Rijksvaccinatie Programma\u2014Nieuw Vaccinatieschema Vanaf 2025 per Geboortejaar. Available online: https:\/\/rijksvaccinatieprogramma.nl\/nieuw-vaccinatieschema-2025."},{"key":"ref_8","unstructured":"Swedish Council on Health Technology A (2009). SBU Systematic Review Summaries. Vaccines to Children: Protective Effect and Adverse Events: A Systematic Review, Swedish Council on Health Technology Assessment (SBU)."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0264-410X(03)00511-5","article-title":"Standardized case definitions of adverse events following immunization (AEFI)","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"key":"ref_10","unstructured":"Netherlands Pharmacovigilance Centre Lareb (2025, June 16). About Lareb. Available online: https:\/\/www.lareb.nl\/en\/pages\/about-lareb."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00431-010-1294-4","article-title":"Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children","volume":"170","author":"Kemmeren","year":"2011","journal-title":"Eur. J. Pediatr."},{"key":"ref_12","unstructured":"Centers for Disease Control and Prevention (CDC) (2025, September 12). About V-Safe, Available online: https:\/\/www.cdc.gov\/vaccine-safety-systems\/v-safe\/index.html#:~:text=Overview,COVID%2D19%20or%20RSV%20vaccine."},{"key":"ref_13","first-page":"CD004407","article-title":"Vaccines for measles, mumps, rubella, and varicella in children","volume":"4","author":"Rivetti","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_14","unstructured":"RIVM (2025, March 31). Rijksvaccinatie Programma\u2014DTP-Vaccinatie. Available online: https:\/\/rijksvaccinatieprogramma.nl\/vaccinaties\/dtp."},{"key":"ref_15","unstructured":"RIVM (2025, March 31). Rijksvaccinatie Programma\u2014De BMR-Prik in Het Kort. Available online: https:\/\/rijksvaccinatieprogramma.nl\/vaccinaties\/bmr."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"van der Kooi, D., van Balveren, L., Boetzkes, S., and van Hunsel, F. (2025). Latentietijden van vermoede bijwerkingen na BMR-vaccinatie in de spontane meldingen van Bijwerkingencentrum Lareb. JGZ Tijdschrift voor Jeugdgezondheidszorg, Springer.","DOI":"10.61431\/0bvgvv70"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1542\/peds.2006-0678","article-title":"Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine","volume":"118","author":"LeBaron","year":"2006","journal-title":"Pediatrics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1542\/peds.106.5.e62","article-title":"Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination","volume":"106","author":"Virtanen","year":"2000","journal-title":"Pediatrics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/INF.0000000000001241","article-title":"Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009","volume":"35","author":"Kuter","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40264-022-01207-x","article-title":"Authors\u2019 Reply to Mungmunpuntipantip et al.\u2019s Comment on \u201cDescription of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands\u201d","volume":"45","author":"Kant","year":"2022","journal-title":"Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/PSY.0b013e3182294a50","article-title":"The nocebo effect and its relevance for clinical practice","volume":"73","author":"Colloca","year":"2011","journal-title":"Psychosom. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Raethke, M., Gorter, J., Kalf, R., van Balveren, L., Jajou, R., and van Hunsel, F. (2025). Frequency, Timing, Burden and Recurrence of Adverse Events Following Immunization After HPV Vaccine Based on a Cohort Event Monitoring Study in The Netherlands. Vaccines, 13.","DOI":"10.3390\/vaccines13080812"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp.70.1.15","article-title":"Additional educational needs in children born to mothers with epilepsy","volume":"70","author":"Adab","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.coph.2018.05.009","article-title":"Effect of sex on vaccination outcomes: Important but frequently overlooked","volume":"41","author":"Harper","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.vaccine.2014.01.010","article-title":"Increased emergency room visits or hospital admissions in females after 12-month MMR vaccination, but no difference after vaccinations given at a younger age","volume":"32","author":"Wilson","year":"2014","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jamainternmed.2019.7194","article-title":"Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All: A Review","volume":"180","author":"Bartz","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2511","DOI":"10.1002\/bdr2.2511","article-title":"Reply to Correspondence on \u201cComparison of Perceived Adverse Events After COVID-19 Vaccination Between Pregnant and NonPregnant Women Using Two Cohort Studies in The Netherlands\u201d","volume":"117","author":"Woestenberg","year":"2025","journal-title":"Birth Defects Res."},{"key":"ref_28","unstructured":"Statistics Netherlands (2025, October 17). How Many Residents of The Netherlands Have a Non-Dutch Background?. Available online: https:\/\/www.cbs.nl\/en-gb\/dossier\/asylum-migration-and-integration\/how-many-residents-of-the-netherlands-have-a-non-dutch-background-#:~:text=A%20total%20of%2016.2%20percent,in%20the%20Netherlands%20as%20immigrants."},{"key":"ref_29","unstructured":"Statistics Netherlands (2025, March 31). Wat Is Het Onderwijs-Niveau van Nederland?. Available online: https:\/\/longreads.cbs.nl\/nederland-in-cijfers-2024\/wat-is-het-onderwijsniveau-van-nederland\/."},{"key":"ref_30","unstructured":"RIVM (2010). Klachten en Kwalen Bij Kinderen in Nederland\u2014Omvang en Gevolgen Ge\u00efnventariseerd, Rijksinstituut voor Volksgezondheid en Miliei. Report No.: RIVM Rapport 260136001\/2010."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","article-title":"Healthy user and related biases in observational studies of preventive interventions: A primer for physicians","volume":"26","author":"Shrank","year":"2011","journal-title":"J. Gen. Intern. Med."},{"key":"ref_32","unstructured":"World Health Organization (WHO) (2019). Causality assessment of an adverse event following immunization (AEFI). User Manual for the Revised WHO Classification, World Health Organization (WHO). 2019 Update."},{"key":"ref_33","unstructured":"Harmark, L. (2025, July 14). Web-Based Intensive Monitoring; A Patient Based Pharmacovigilance Tool: Rijksuniversiteit Groningen. Available online: https:\/\/www.rug.nl\/news\/2012\/06\/22_harmark?lang=en."},{"key":"ref_34","unstructured":"RIVM (2025, March 31). Rijksvaccinatie Programma\u2014Onderbouwing en Wijzigingen in Historisch Overzicht. Available online: https:\/\/rijksvaccinatieprogramma.nl\/professionals\/richtlijnen\/uitvoering\/3-onderbouwing-en-wijzigingen."},{"key":"ref_35","unstructured":"The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2025, July 14). Welcome to MedDRA. Available online: https:\/\/www.meddra.org\/."},{"key":"ref_36","unstructured":"KNMP (2025, September 12). The G-Standaard: The Medicines Standard in Healthcare. Available online: https:\/\/www.knmp.nl\/over-de-knmp\/producten-en-diensten\/wat-is-de-g-standaard."},{"key":"ref_37","unstructured":"CIOMS Working Group VIII (2010). Practical Aspects of Signal Detection in Pharmacovigilance. Report of CIOMS Working Group VIII, CIOMS Working Group VIII. Report No.: 9290360828."},{"key":"ref_38","unstructured":"RIVM (2025, July 15). Vaccinatietechniek. Available online: https:\/\/rijksvaccinatieprogramma.nl\/professionals\/richtlijnen\/uitvoering\/9-vaccinatietechniek."},{"key":"ref_39","unstructured":"Statistics Netherlands (2025, September 12). Opleidingsniveau. Available online: https:\/\/www.cbs.nl\/nl-nl\/nieuws\/2023\/48\/hoge-tevredenheid-ondanks-lage-materiele-welvaart-in-caribisch-nederland\/opleidingsniveau."},{"key":"ref_40","unstructured":"Statistics Netherlands (2025, September 12). Microdata: Zelf Onderzoek Doen. Available online: https:\/\/www.cbs.nl\/nl-nl\/onze-diensten\/maatwerk-en-microdata\/microdata-zelf-onderzoek-doen."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/ajpas\/2019\/v5i230132","article-title":"Diagnosing Multicollinearity of Logistic Regression Model","volume":"5","author":"Senaviratna","year":"2019","journal-title":"Asian J. Probab. Stat."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/11\/1635\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:47:49Z","timestamp":1761760069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/11\/1635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ph18111635"],"URL":"https:\/\/doi.org\/10.3390\/ph18111635","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}